Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDX-101 in Relapsed/Refractory Multiple Myeloma
NCT00293111Phase 2Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Feb 2002
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-etodolac in multiple myeloma (MM), sponsored by Cephalon, Inc.. Started Feb 2002; status: terminated.
02
Drugs
r-etodolac
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00293111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293111.